All Online

1 - 12 of 12 results

Refine

Active filters

Cardiovascular Outcomes Trials
1 CME CREDIT

This talk will cover recent clinical trials presented at the ADA in 2019 that have an impact on the management of diabetes, such as cardiovascular outcomes trials and the first oral GLP-1 RA phase 3 data. The faculty will take you through the latest guidelines from the ADA regarding the management of type 2 diabetes and describe how recent clinical trial data has been integrated in to these guidelines. After this meeting review, you will be equipped to manage type 2 diabetes based on these guidelines.


1 CME CREDIT

This talk will cover recent clinical trials presented at the ADA in 2019 that have an impact on the management of diabetes, such as cardiovascular outcomes trials and the first oral GLP-1 RA phase 3 data. The faculty will take you through the latest guidelines from the ADA regarding the management of type 2 diabetes and describe how recent clinical trial data has been integrated in to these guidelines. After this meeting review, you will be equipped to manage type 2 diabetes based on these guidelines. Please note that any data, indications, and guidelines presented in this activity are current as of the recording/release on February 7, 2020, and they are subject to change as new information is published.


0.25 CME CREDIT

Listen to this podcast for a concise summary of the latest clinical practice guidelines for identifying glycemic targets and managing T2DM in various patient populations including, older adults, individuals with increased cardiac or renal risk, and those at risk for hypoglycemic events.


0.75 CME CREDIT

Obesity and Diabetes Update

0.75 CME/MOC
0.75 AANP | 0.28 Pharmacology

Dr. Martin Abrahamson will review the pathophysiology of type 2 diabetes, discuss non-insulin treatments, and explore the most recent guidelines and recommendations for advancing treatment in people with type 2 diabetes to achieve glycemic goals. Dr. Frank Domino will then review a basic framework for counseling patients on weight loss, including a discussion of best evidence on diet, exercise, and appropriate use of medication. Please note that any data, indications, and guidelines presented in this activity are current as of the recording/release on 12/03/2020, and they are subject to change as new information is published.


0.5 CME CREDIT

In this clinical coffee break, cardiologist Ty Gluckman and endocrinologist Archana Sadhu will explain why glucagon like peptide-1 receptor agonists (GLP-1 RA) are becoming increasingly prominent in diabetes algorithms and cardiovascular risk reduction. Faculty will review the clinical trial data on this class of medications as well as the mechanisms by which GLP-1 RA provide cardiovascular benefit. You will have the opportunity to engage with this activity, viewing resources and testing your knowledge with interactive questions and cases.


1 CME CREDIT

Over ten percent of the U.S. population suffers disproportionate cardiometabolic risk because of their type 2 diabetes (T2DM). In light of recent data, GLP-1 receptor agonists (GLP-1 RAs) have taken on a more prominent role in T2DM management algorithms. This session will discuss how you can distinguish among GLP-1 RAs and use them in your practice to help manage the risks that these patients face beyond glucose control. A member of the Diabetes Sisters organization will also be joining us to discuss their experience with starting a GLP-1 RA as a patient.


0.25 CME CREDIT

GLP-1 Receptor Agonists: Overcoming Barriers (Podcast)

0.25 CME/MOC
0.25 AANP | 0.25 Pharmacology

With the growing role of GLP-1 RAs in the management of diabetes, primary care providers are likely to find themselves discussing this class of medications with their patients. In this podcast, Dr. Michelle Magee will focus on barriers that patients may face to starting a GLP-1 RA and common questions that emerge in patient teaching. Faculty will review ways to troubleshoot these challenges and empower the clinician to engage in effective dialogue around this drug class. Please note that any data, indications, and guidelines presented in this activity are current as of the recording on 11/18/2020 and they are subject to change as new information is published.


0.25 CME CREDIT

GLP-1 Receptor Agonists: A Cardiology Perspective (Podcast)

0.25 CME/MOC
0.25 AANP | 0.25 Pharmacology

In this podcast, cardiologist Ty Gluckman will take a deep dive into the cardiology benefits of glucagon like peptide-1 receptor agonists (GLP-1 RA). He will review the clinical trial data which has resulted in GLP-1 RA incorporation into guidelines, which address patients who have both diabetes and atherosclerotic cardiovascular disease. Dr. Gluckman will bring the perspective of a cardiologist into the discussion of these agents with emerging significance in cardiovascular risk reduction.


GLP-1 Receptor Agonists: A Podcast Series

0.75 CME/MOC
0.85 AANP | 0.85 Pharmacology

This podcast series will provide you with on the go learning covering the key points about GLP-1 receptor agonists (GLP-1 RAs). Dr. Michelle Magee will focus on barriers that patients may face to starting a GLP-1 RA and common questions that emerge in patient teaching. Cardiologist Ty Gluckman will take a deep dive into the cardiology benefits and indications for GLP-1 RAs. A FAQ session with Dr. Richard Pratley will answer Pri-Med learner questions about GLP-1 RAs.


Nurse explaining the use of diabetic equipment to a patient
0.5 CME CREDIT

Time to meet your new patient! In this interactive activity, you will be guided through the case of a patient with type 2 diabetes at high-risk for atherosclerotic cardiovascular disease (ASCVD) via a series of questions and complementary videos. Questions will test your strengths and weaknesses around diabetes management, with some questions and feedback tailored directly to your management choices. After each question, you will be presented with learning moments designed to help increase your confidence managing patients with type 2 diabetes and reducing cardiovascular risk.


0.35 CME CREDIT

In this podcast, Dr. Richard Pratley will answer Pri-Med learner questions submitted during recent CME sessions focusing on glucagon like peptide-1 receptor agonists (GLP-1 RAs). Join us for expert answers to questions about who can benefit from GLP-1 RAs, the safety of these medications in different populations, and much more. Please note that any data, indications, and guidelines presented in this activity are current as of the recording on 11/10/2020 and they are subject to change as new information is published.


1 CME CREDIT

During this clinical coffee break, Dr. M. Susan Burke, and Elizabeth Haftel, a clinical pharmacist and certified diabetes educator, will discuss practical strategies for using GLP-1 receptor agonists in your patients with diabetes. They will discuss how this class of medications can benefit certain patients. To illustrate the process, faculty will walk through a patient case. You will have the opportunity to engage with this activity, view resources and test your knowledge with interactive questions.